Exclusive Summary

• • A Next generation CEA TCE: With features of “plus” signal stimulation, which is likely to overcome the limitations of TA*4-1BB or TA*CD3 bispecific antibodies in the solid tumor. Thanks to its secondary signal 4-1BB, this drug has the potential to mitigate the exhaustion after multiple rounds of activation and overcome the defect of low efficacy caused by insufficient T-cell infiltration in cold tumors.
• • Strong Efficacy and Safety: Strictly tumor antigen-dependent CD3/CD137 dual activation.
• • Logic-gate controlled activation: Only after the TAA of TCE binds to the target protein can it be endowed with the subsequent ability to bind to CD3.
• • IgG CMC Platform: IGG-like structure with completely silent Fc.